22:26 , Apr 1, 2019 |  BioCentury  |  Finance

Backing Cambridge's AI boom

After raising £150 million ($196 million) in its latest fund, Cambridge Innovation Capital will be keeping an eye on how artificial intelligence and machine learning technology can be applied to the life science sector. CIC...
19:16 , Apr 1, 2019 |  BC Extra  |  Financial News

Cambridge Innovation raises £150M

Cambridge Innovation raised £150 million ($196 million) to back its portfolio of 25 companies and invest in spinouts from the University of Cambridge and Cambridge area. Cambridge Innovation Capital plc CEO Victor Christou told BioCentury...
01:57 , Mar 22, 2019 |  BC Innovations  |  Product Development

Regulating regeneration in Europe

As Europe rethinks its policies on regenerative medicine, the question is whether it can regain its footing in a competitive field it once led, given the in-built inconsistencies across the EU’s member states. Europe positioned...
21:51 , Feb 22, 2019 |  BioCentury  |  Emerging Company Profile

Gyroscope complements dry AMD

Gyroscope Therapeutics Ltd.’s complement-targeting gene therapy for dry age-related macular degeneration could have an edge over competing therapies that are dosed chronically or target complement downstream of its key immune mediators. On Feb. 19, Gyroscope...
23:58 , Nov 28, 2018 |  BC Extra  |  Preclinical News

Placental organoid could improve preeclampsia therapies

A placenta-like organoid developed by a University of Cambridge team could improve understanding of maternal-fetal first-trimester disorders like preeclampsia and provide a model to study therapies to treat first-trimester complications. Challenges in preeclampsia and other...
22:11 , Nov 7, 2018 |  BC Innovations  |  Translation in Brief

M is for Chemoproteomic Momentum

An October Nature paper from a University of Cambridge team is the second in as many years to highlight the utility of functionalizing methionine, an amino acid that has garnered less attention than others in...
22:22 , Nov 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

New Therapeutic Targets and Biomarkers: October 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October. Therapeutic targets are defined as any protein, gene or other molecule...
01:06 , Jun 12, 2018 |  BC Extra  |  Preclinical News

Investors skittish again over preclinical CRISPR studies

Investor response to a pair of papers linking CRISPR-based gene editing to cancer are the latest example of a market overreaction to preclinical news on the still-nascent technology. The papers unearth a potential safety concern...
19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
20:39 , May 11, 2018 |  BioCentury  |  Emerging Company Profile

Enterin the gut

Enterin Inc. has a new twist on the longstanding Parkinson’s disease target alpha synuclein. The biotech is inhibiting the protein’s accumulation in intestinal nerves rather than in the brain, with the goal of treating constipation...